ISOLYTE S (MULTI-ELECTROLYTE INJECTION) 530 MG / 100 ML — DIN 01931628
SODIUM CHLORIDE : 530 MG / 100 ML POTASSIUM CHLORIDE : 37 MG / 100 ML SODIUM ACETATE : 370 MG / 100 ML MAGNESIUM CHLORIDE : 30 MG / 100 ML SODIUM GLUCONATE : 500 MG / 100 ML · B. BRAUN MEDICAL INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ISOLYTE S (MULTI-ELECTROLYTE INJECTION)?
ISOLYTE S (MULTI-ELECTROLYTE INJECTION) 530 MG / 100 ML contains SODIUM CHLORIDE : 530 MG / 100 ML POTASSIUM CHLORIDE : 37 MG / 100 ML SODIUM ACETATE : 370 MG / 100 ML MAGNESIUM CHLORIDE : 30 MG / 100 ML SODIUM GLUCONATE : 500 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 01931628, held by B. BRAUN MEDICAL INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 17-Jun-1998. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does Electrolytes cost around the world?
Electrolytes is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Iceland publishes a max wholesale; Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Iceland | max wholesale | 2 | 2 | ISK███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
3 pack listings across 3 brand entries and 2 price bases, refreshed 02 Sep 2026. Ranges span every Electrolytes pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Electrolytes in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Electrolytes, across 20 DINs, of which 10 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAXTER CORPORATION | 10 | 6 | (20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP, (40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP, (40 MMOLS/L) POTASSIUM CHLORIDE IN LACTATED RINGER'S INJECTION USP, LACTATED RINGER'S INJECTION, USP, MULTIPLE ELECTROLYTE ADDITIVE LIQ FORMULA 1, +5 more | Sourceable in Canada |
| B. BRAUN MEDICAL INC | 5 | 3 | HYPERLYTE CR MULTI-ELECTROLYTE CONCENTRATE, ISOLYTE S (MULTI-ELECTROLYTE INJECTION), ISOLYTE S PH 7.4 (MULTI-ELECTROLYTE INJECTION), LACTATED RINGER'S INJECTION USP, RINGER'S INJECTION USP | Sourceable in Canada |
| ICU MEDICAL CANADA INC | 4 | 1 | LACTATED RINGER'S INJECTION, NORMOSOL-R, POTASSIUM CHLORIDE 20 MEQ IN 0.9% SODIUM CHLORIDE, POTASSIUM CHLORIDE 40 MEQ IN 0.9% SODIUM CHLORIDE | Sourceable in Canada |
| HOSPIRA HEALTHCARE ULC | 1 | 0 | PLEGISOL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 530 MG / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Electrolytes |
|---|---|
| ATC code | B05BB01 |
| AHFS class | 40:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01931628 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1931628 |
| Brand name | ISOLYTE S (MULTI-ELECTROLYTE INJECTION) |
| Generic / active ingredient | SODIUM CHLORIDE : 530 MG / 100 ML POTASSIUM CHLORIDE : 37 MG / 100 ML SODIUM ACETATE : 370 MG / 100 ML MAGNESIUM CHLORIDE : 30 MG / 100 ML SODIUM GLUCONATE : 500 MG / 100 ML |
| Market authorization holder | B. BRAUN MEDICAL INC |
| Health Canada schedule | Ethical |
| ATC code | B05BB01 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05BB |
| Current status | MARKETED |
| Status date | 17-Jun-1998 |
| Original market date | 1992-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
10 of 20 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| (20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP | 150 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 00786209 |
| (40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP | 300 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | 00786217 |
| ISOLYTE S PH 7.4 (MULTI-ELECTROLYTE INJECTION) | 820 MCG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | 01931679 |
| LACTATED RINGER'S INJECTION | 3.1 MG | SOLUTION | ICU MEDICAL CANADA INC | MARKETED | 00039470 |
| LACTATED RINGER'S INJECTION USP | 20 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | 01931636 |
| LACTATED RINGER'S INJECTION, USP | 310 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 00061085 |
| PLASMA-LYTE A INJECTION | 30 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02339358 |
| POTASSIUM CHLORIDE IN LACTATED RINGER'S INJECTION | 20 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | 02243421 |
| POTASSIUM CHLORIDE IN SODIUM CHLORIDE INJECTION USP | 450 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02269414 |
| (40 MMOLS/L) POTASSIUM CHLORIDE IN LACTATED RINGER'S INJECTION USP | 310 MG / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | 02246134 |
2 · Same class — other molecules in ATC B05BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Electrolytes With Carbohydrates | (20 MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP · (20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP · (20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP · (20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.2% SODIUM CHLORIDE INJECTION USP · +66 more | 70 | 17 | Yes |
| Electrolytes | (20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP · (40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP · (40 MMOLS/L) POTASSIUM CHLORIDE IN LACTATED RINGER'S INJECTION USP · HYPERLYTE CR MULTI-ELECTROLYTE CONCENTRATE · +16 more | 20 | 10 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05BA | Amino Acids · Carbohydrates · Combinations · Fat Emulsions | 150 | 38 |
| B05BC | Carbamide · Carbamide, Combinations · Mannitol | 11 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ISOLYTE S (MULTI-ELECTROLYTE INJECTION) called?
The same molecule, Electrolytes, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ADDAMEL AMP. | Latin | Saudi Arabia |
| Hypertonic | Latin | Iceland |
| Ringer lactat Hartmann | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.